Krittamate Chatdamrongsakool
Krittamate Chatdamrongsakool has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Duangjai Todsaporn
Center of Excellence in Structural and Computational Biology, Department of Biochemistry, Faculty of Science
1 shared publication- Hasriadi
Animal Models of Chronic Inflammation-Associated Diseases for Drug Discovery Research Unit, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication - Khomsak Srilanchakon
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
1 shared publication - Nattakarn Numsriskulrat
Division of Pediatric Endocrinology, Department of Pediatrics, Faculty of Medicine , Chulalongkorn University , Bangkok , Thailand
1 shared publication - Opa Vajragupta
Center of Excellence in Natural Products for Ageing and Chronic Diseases, Chulalongkorn University, Bangkok 10330, Thailand
1 shared publication - Pasarapa Towiwat
Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
1 shared publication
Latest Publications
- 13 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 45-58
3-(4-Hydroxyphenyl-1,2,3-Triazol-1-yl)Quinuclidine, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, Attenuates Inflammatory Pain with a Favorable Central Nervous System Safety Profile in Mice
Selective α7 nicotinic acetylcholine receptors (α7 nAChRs) have emerged as therapeutic targets for managing various pain conditions, including inflammatory pain. Activation of α7 nAChRs by selective agonists has been shown to exert both antinociceptive and anti-inflammatory effects. In this study, we investigate the pharmacological effects of 3-(4-Hydroxyphenyl-1,2,3-triazol-1-yl)-quinuclidine (QND8), a selective and potent α7 nAChR agonist, in a murine model of carrageenan-induced inflammatory pain and evaluated its central nervous system (CNS) safety profile. QND8 significantly alleviated thermal and mechanical hyperalgesia at doses of 1, 3, and 10 mg/kg, and reduced carrageenan-induced paw edema at doses of 10 mg/kg. Importantly, QND8 exhibited these effects without impairing motor coordination and general behaviors, as demonstrated by the rotarod test and automated home cage behavioral analysis. These findings highlight QND8 as a promising preclinical analgesic candidate with anti-inflammatory efficacy and a favorable CNS safety profile. Computational modeling further revealed a stable and high-affinity binding of QND8 within the orthosteric site of α7 nAChR, consistent with its selective agonist activity. The results support further development of QND8 as a selective α7 nAChR-targeting therapeutic for inflammatory pain.
- 13 December 2025
- Published by American Chemical Society (ACS) in ACS Pharmacology & Translational Science
- Vol. 9 (1) , 45-58
3-(4-Hydroxyphenyl-1,2,3-Triazol-1-yl)Quinuclidine, a Selective α7 Nicotinic Acetylcholine Receptor Agonist, Attenuates Inflammatory Pain with a Favorable Central Nervous System Safety Profile in Mice
Selective α7 nicotinic acetylcholine receptors (α7 nAChRs) have emerged as therapeutic targets for managing various pain conditions, including inflammatory pain. Activation of α7 nAChRs by selective agonists has been shown to exert both antinociceptive and anti-inflammatory effects. In this study, we investigate the pharmacological effects of 3-(4-Hydroxyphenyl-1,2,3-triazol-1-yl)-quinuclidine (QND8), a selective and potent α7 nAChR agonist, in a murine model of carrageenan-induced inflammatory pain and evaluated its central nervous system (CNS) safety profile. QND8 significantly alleviated thermal and mechanical hyperalgesia at doses of 1, 3, and 10 mg/kg, and reduced carrageenan-induced paw edema at doses of 10 mg/kg. Importantly, QND8 exhibited these effects without impairing motor coordination and general behaviors, as demonstrated by the rotarod test and automated home cage behavioral analysis. These findings highlight QND8 as a promising preclinical analgesic candidate with anti-inflammatory efficacy and a favorable CNS safety profile. Computational modeling further revealed a stable and high-affinity binding of QND8 within the orthosteric site of α7 nAChR, consistent with its selective agonist activity. The results support further development of QND8 as a selective α7 nAChR-targeting therapeutic for inflammatory pain.
- Open Access
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 207-212
Treatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.
- 31 August 2025
- Published by Korean Society of Pediatric Endocrinology in Annals of Pediatric Endocrinology & Metabolism
- Vol. 30 (4) , 207-212
Open AccessTreatment of overweight and obese girls experiencing central precocious puberty: a comparison of the effectiveness of leuprolide acetate and triptorelin pamoate
Purpose: Gonadotropin-releasing hormone agonists are the standard treatment for central precocious puberty (CPP). These agonists include leuprolide acetate and triptorelin pamoate, but research data for the relative effectiveness of these 2 treatments in overweight and obese girls experiencing CPP are lacking. In this study, we compared the effectiveness of these 2 therapeutics, leuprolide acetate and triptorelin pamoate, in the treatment of overweight and obese girls affected by CPP.Methods: We enrolled 69 overweight and obese girls with CPP in this retrospective cohort study and classified these participants according to their baseline body mass index (BMI) status, BMI≥1 standard deviation scoer. Leuprolide acetate was administered to 48 of the participants, and the other 21 were treated with triptorelin pamoate. The anthropometric measurements were compared at the beginning and conclusion of the therapy, and luteinizing hormone (LH) suppression levels were assessed 6 months following the completion of treatment.Results: Leuprolide acetate and triptorelin pamoate substantially suppressed LH when administered to overweight and obese girls with CPP. The predicted adult height (PAH) at the conclusion of treatment was comparable between the 2 groups.Conclusion: There was no significant difference in the level of LH suppression and PAH between the 2 groups, overweight and obese girls with CPP treated with leuprolide acetate and those treated with triptorelin pamoate.